-
公开(公告)号:US20210388382A1
公开(公告)日:2021-12-16
申请号:US17053733
申请日:2019-05-08
Applicant: Neuracle Science Co., Ltd. , Neuracle Genetics
Inventor: Jong-Mook KIM , Dong Sik KIM , Juwon SHIM , Soon-gu KWON
Abstract: The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.
-
公开(公告)号:US20200223914A1
公开(公告)日:2020-07-16
申请号:US16626625
申请日:2018-06-27
Inventor: Bongcheol KIM , Eun Bee CHO , Dong Sik KIM , Jae-Keun LEE , Soon-gu KWON , Jae Young SEONG , Juwon SHIM , Tae Woo KIM , Shin-hyuk KANG
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
-
公开(公告)号:US20230348584A1
公开(公告)日:2023-11-02
申请号:US18158259
申请日:2023-01-23
Applicant: Neuracle Science Co., Ltd.
Inventor: Bongcheol KIM , Eun Bee CHO , Dong Sik KIM , Jae-Keun LEE , Soon-gu KWON , Jae Young SEONG , Juwon SHIM , Tae Woo KIM , Shin-hyuk KANG
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
-
公开(公告)号:US20220064277A1
公开(公告)日:2022-03-03
申请号:US17418681
申请日:2019-12-26
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor: Bongcheol KIM , Dong Sik KIM , Jae-Keun LEE , Juwon SHIM
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.
-
-
-